Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03844620 |
|
Recruitment Status :
Recruiting
First Posted : February 18, 2019
Last Update Posted : February 18, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Refractory Colorectal Carcinoma Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 | Other: Best Practice Other: Laboratory Procedure Other: Quality-of-Life Assessment Other: Questionnaire Administration Drug: Regorafenib Drug: Trifluridine and Tipiracil Hydrochloride | Phase 2 |
PRIMARY OBJECTIVES:
I. To evaluate the ability of early change in circulating tumor-derived deoxyribonucleic acid (ctDNA) (ctDNA-early dynamic changes [EDC] or A ctDNA) during systemic therapy in metastatic colorectal cancer (mCRC) to predict radiographic progression (only standard of care [SOC] arm).
II. To evaluate differences in clinically significant treatment-related adverse events (TRAEs) of interest (grade 3/4 toxicity per National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, intolerable grade 2 toxicity or any toxicity requiring dose reduction) between SOC and ctDNA arm.
SECONDARY OBJECTIVES:
I. To evaluate differences in patient-reported outcomes (PROs) between SOC and ctDNA arm.
II. To compare Response Evaluation Criteria in Solid Tumors (RECIST) duration of complete response (DCR) (partial response [PR] and stable disease [SD]) between SOC and ctDNA arm.
III. To evaluate differences in overall survival (OS) between SOC and ctDNA arm.
IV. To evaluate differences between SOC and ctDNA arm with regards to emergency severity indices (ESIs): Hospitalizations/emergency room visits.
V. To evaluate differences between SOC and ctDNA arm with regards to ESIs: Need for medical interventions (blood transfusions and intravenous [IV] hydration).
VI. To evaluate cost-effectiveness associated with both strategies, i.e. SOC strategy and ctDNA strategy in treatment of mCRC.
VII. To compare time to deterioration of Eastern Cooperative Oncology Group (ECOG) performance status (PS) between SOC and ctDNA arms.
VIII. To compare time to deterioration of PROs between SOC and ctDNA arms. IX. To evaluate differences in proportion of patients referred to clinical trial after completion of therapy between SOC and ctDNA arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo ctDNA testing and depending on the results receive either regorafenib orally (PO) on days 1-21, trifluridine and tipiracil hydrochloride (TAS-102) PO twice daily (BID) on days 1-5 and 8-12, or regorafenib PO on days 1-21 and TAS-102 PO BID on days 1-5 and 8-12. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive regorafenib or TAS-102 per standard of care. Treatment continues in the event of disease stability or regression as per discretion of treating physician or absence of disease progression.
After completion of study treatment, patients are followed up at 2 weeks and then monthly for up to 18 months.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Study Evaluating Tailoring of Advanced/Metastatic Colorectal Cancer (CRC) Therapy Using Circulating Cell-Free Tumor DNA (ctDNA) (TACT-D) |
| Actual Study Start Date : | January 29, 2019 |
| Estimated Primary Completion Date : | August 31, 2020 |
| Estimated Study Completion Date : | August 31, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm I (ctDNA testing, regorafenib, TAS-102)
Patients undergo ctDNA testing and depending on the results receive either regorafenib PO on days 1-21, TAS-102 PO BID on days 1-5 and 8-12, or regorafenib PO on days 1-21 and TAS-102 PO BID on days 1-5 and 8-12. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
|
Other: Laboratory Procedure
Undergo ctDNA testing
Other Names:
Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies Drug: Regorafenib Given PO
Other Names:
Drug: Trifluridine and Tipiracil Hydrochloride Given PO
Other Names:
|
|
Active Comparator: Arm II (SOC)
Patients receive regorafenib or TAS-102 per standard of care. Treatment continues in the event of disease stability or regression as per discretion of treating physician or absence of disease progression.
|
Other: Best Practice
Receive SOC
Other Names:
Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies Drug: Regorafenib Given PO
Other Names:
Drug: Trifluridine and Tipiracil Hydrochloride Given PO
Other Names:
|
- Early change in circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) as a predictor of radiographic progression (Arm II-SOC) [ Time Frame: First 4 months after treatment initiation ]Number of patients with rise in ctDNA level will be compared to Number of patients with progression of disease on scans.
- Treatment-related adverse events (TRAEs) of interest (grade 3/4 toxicity, intolerable grade 2 toxicity, or any toxicity requiring dose reduction) between arms [ Time Frame: First 4 months after treatment initiation ]Will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. To compare the proportions of patients who have experienced TRAEs of interest within the first 4 months between the two treatment arms, Fisher's exact test will be used.
- Mean patient-reported outcomes (PROs) score as per MD Anderson Symptom Inventory (MDASI-GI) [ Time Frame: Up to 18 months ]Mean PROs scores measured by MDASI-GI scales will be compared between arms
- Mean patient-reported outcomes (PROs) score as per PRO-CTCAE [ Time Frame: Up to 18 months ]Mean PROs scores measured by PRO-CTCAE scales will be compared between arms
- Percentage of patients with partial response (PR) [ Time Frame: Up to 18 months ]Percentage of patients with PR will be compared between arms
- Percentage of patients with stable disease (SD) [ Time Frame: Up to 18 months ]Percentage of patients with SD will be compared between arms
- Overall survival (OS) [ Time Frame: Up to 18 months ]OS will be compared between arms.
- Percentage of patients who present with events of special interest (ESIs) [ Time Frame: Up to 18 months ]Percentage of patients who present with ESIs [described as either Hospitalizations/emergency room visits or need for medical interventions (blood transfusions and IV hydration)] will be compared between arms
- Cost measured in US dollars [ Time Frame: Up to 18 months ]Cost measured in US dollars will be compared between arms
- Median time to performance status deterioration [ Time Frame: Up to 18 months ]Will be compared between arms.
- Median time to PRO deterioration [ Time Frame: Up to 18 months ]Will be compared between arms.
- Proportion of patients referred to clinical trial [ Time Frame: Up to 18 months ]Will be compared in both arms.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed colorectal cancer.
- Patients must have advanced or metastatic disease with no curative options.
- Patients must have radiographically evaluable disease.
- Patients must have had at least 2 prior therapies for mCRC (including fluorouracil [5-FU], oxaliplatin, irinotecan, bevacizumab; cetuximab/panitumumab [for RAS wild type (WT) patients]) and have either progressed on or intolerant to these agents or use of these agents is contraindicated.
- Patients must be clinically eligible for either regorafenib or TAS-102 as per their treating physician.
- Patients must have a negative serum pregnancy test done less than are equal to 14 days prior to randomization for women of childbearing potential only. Women of child bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry for the duration of study participation.
- Patients must have ability to complete questionnaire(s) by themselves or with assistance.
- Patients must have ability to provide informed written consent.
- Patients must be willing to return to enrolling institution for follow-up as per study schedule.
- Patients must be willing to provide blood samples for correlative studies.
- Any of the following: Pregnant or nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception.
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
Exclusion Criteria:
- Patient who have received prior TAS-102 are eligible to enroll on the study if they can receive regorafenib and vice-versa. Otherwise these patients will be excluded from the study.
- Congestive heart failure > New York Heart Association (NYHA) class 2, unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months) or myocardial infarction less than 3 months prior to randomization.
- Ongoing infection > grade 2 CTCAE version 4.0.
- Symptomatic metastatic brain or meningeal tumors unless the patient is > 3 months from definitive therapy, has a negative imaging study within 4 weeks of randomization and is clinically stable with respect to brain lesions at the time of randomization (Note: patient must not be undergoing acute steroid therapy or taper [chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies]).
- Renal failure requiring hematological or peritoneal dialysis.
- Patients unable to swallow oral medications.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03844620
| Contact: Kanwal Raghav | 713-792-2828 | kpraghav@mdanderson.org |
| United States, Texas | |
| M D Anderson Cancer Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Kanwal P. Raghav 713-792-2828 | |
| Principal Investigator: Kanwal P. Raghav | |
| Principal Investigator: | Kanwal Raghav | M.D. Anderson Cancer Center |
Additional Information:
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT03844620 History of Changes |
| Other Study ID Numbers: |
2018-0233 NCI-2019-00246 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2018-0233 ( Other Identifier: M D Anderson Cancer Center ) P30CA016672 ( U.S. NIH Grant/Contract ) |
| First Posted: | February 18, 2019 Key Record Dates |
| Last Update Posted: | February 18, 2019 |
| Last Verified: | February 2019 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases |
Colonic Diseases Intestinal Diseases Rectal Diseases Trifluridine Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents |